Author

Katherine Kudrycki

Observed names: K. Kudrycki, Katherine E. Kudrycki, Kudrycki, Katherine

Institution: Rosa (United States)

Observed institutions: University of Kentucky, Rosa (United States)

OpenAlex ID: A5006934202

Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level

2020 · Ronald B. Moss, Meghan McCabe Pryor, et al. · PLoS ONE · 48

Levels of nerve growth factor and neurotrophin-3 are affected differentially by the presence of p75 in sympathetic neurons in vivo

2000 · Susan M.W. Harrison, Marc E. Jones, et al. · The Journal of Comparative Neurology · 23

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates

2022 · Vidya Ramakrishnan, Christina Friedrich, et al. · CPT Pharmacometrics & Systems Pharmacology · 19

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics

2017 · Jeffrey E Ming, Ruth E Abrams, et al. · Gene Regulation and Systems Biology · 17

Life scientists improve QSP model quality and impact

2024 · Katherine Kudrycki, Christina Friedrich, et al. · Frontiers in Pharmacology · 2

In silico modelling of skin sensitisation

2007 · C. MacKay, S. Bajaria, et al. · Toxicology · 2

Brief Report: Higher Fentanyl Exposures Require Higher Doses of Naloxone for Successful Reversals in a Quantitative Systems Pharmacology Model

2022 · Ronald B. Moss, Meghan McCabe Pryor, et al. · Addiction Research and Adolescent Behaviour · 1

Modeling shows the NK3R antagonist, ACER-801, reduces treatment-induced vasomotor symptoms.

2021 · Rebecca Baillie, Chris Schelling, et al. · Journal of Clinical Oncology · 1

A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor

2024 · Dan Lu, Robert Sheehan, et al.

LB1573 Evaluation of a novel therapy and identification of uncertainties critical to efficacy and competitive differentiation in a Psoriasis PhysioPD™ Platform

2018 · M. Weis, K. Kudrycki, et al. · Journal of Investigative Dermatology

563 Mechanistic modeling facilitates identification of key pathways involved in dermal aging and potential new targets for anti-aging intervention

2017 · K. Kudrycki, M. Weis, et al. · Journal of Investigative Dermatology

717 Mechanistic physiological modeling as a tool for enhancing dermatology research

2017 · C. Friedrich, K. Kudrycki, et al. · Journal of Investigative Dermatology

Title: DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY PLATFORM TO SUPPORT TRANSLATIONAL RESEARCH AND CLINICAL DEVELOPMENT IN IMMUNO-ONCOLOGY

2015 · Bárbara Schmidt, David Bartlett, et al.

Biosimulations Predict that Rituximab is More Efficacious than Other Standards of Care in Rheumatoid Arthritis Patients with Severe Disease

2007 · Kosmas Kretsos, Daniel L. Young, et al. · Clinical Immunology

Works count: 17

Citation count: 113

H-index: 4

I10-index: 4